None listed
Conditions
Interventions
Drug : Take anastrozole (Anasto tab. 1mg, Boryeong Pharmaceutical) once a day for a period of at least 2 weeks to 4 weeks (1 month) until the day before surgery, regardless of the meal
Sponsors
Yonsei University Health System, Severance Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Those who have voluntarily agreed in writing to participate in this study 2) Aged 19 ~ 70 years old (including women who do not have ovarian function due to ovarian resection, etc.) 3) Stage I-IIIA, hormone-positive, HER2 non-hyper-expressing (negative) primary breast cancer 4) Patients who have consented to undergo surgery and multigene assay 5) Those who understand the contents of the clinical trial, are cooperative with the conduct of the trial, and to be judged to be able to participate until the end of the study
Exclusion criteria
Exclusion criteria: 1) Pregnant or lactating women 2) Patients who have undergone neoadjuvant therapy 3) Prior cancer history within 5 years (skin cancer, papillary thyroid cancer, cervical carcinoma in situ can be included) 4) Others who are judged to be inappropriate by the researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of risk groups according to the multi-genetic test method according to Ki67 changes after 2-4 weeks of administration of anastrozole | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgical margin positivity rate;Rate of adverse drug reactions (bone pain, joint pain, etc.);Build-ups anastrozole-resistant breast cancer cell lines and organoid | — |
Countries
Korea, Republic of
Contacts
Public ContactKyoungju Beak
Yonsei University Health System, Severance Hospital
Outcome results
None listed